1
|
Tavakkol E, Kihira S, McArthur M, Polson J, Zhang H, Arnold CW, Yoo B, Linetsky M, Salehi B, Ledbetter L, Kim C, Jahan R, Duckwiler G, Saver JL, Liebeskind DS, Nael K. Automated Assessment of the DWI-FLAIR Mismatch in Patients with Acute Ischemic Stroke: Added Value to Routine Clinical Practice. AJNR Am J Neuroradiol 2024; 45:562-567. [PMID: 38290738 DOI: 10.3174/ajnr.a8170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 01/12/2024] [Indexed: 02/01/2024]
Abstract
BACKGROUND AND PURPOSE The DWI-FLAIR mismatch is used to determine thrombolytic eligibility in patients with acute ischemic stroke when the time since stroke onset is unknown. Commercial software packages have been developed for automated DWI-FLAIR classification. We aimed to use e-Stroke software for automated classification of the DWI-FLAIR mismatch in a cohort of patients with acute ischemic stroke and in a comparative analysis with 2 expert neuroradiologists. MATERIALS AND METHODS In this retrospective study, patients with acute ischemic stroke who had MR imaging and known time since stroke onset were included. The DWI-FLAIR mismatch was evaluated by 2 neuroradiologists blinded to the time since stroke onset and automatically by the e-Stroke software. After 4 weeks, the neuroradiologists re-evaluated the MR images, this time equipped with automated predicted e-Stroke results as a computer-assisted tool. Diagnostic performances of e-Stroke software and the neuroradiologists were evaluated for prediction of DWI-FLAIR mismatch status. RESULTS A total of 157 patients met the inclusion criteria. A total of 82 patients (52%) had a time since stroke onset of ≤4.5 hours. By means of consensus reads, 81 patients (51.5%) had a DWI-FLAIR mismatch. The diagnostic accuracy (area under the curve/sensitivity/specificity) of e-Stroke software for the determination of the DWI-FLAIR mismatch was 0.72/90.0/53.9. The diagnostic accuracy (area under the curve/sensitivity/specificity) for neuroradiologists 1 and 2 was 0.76/69.1/84.2 and 0.82/91.4/73.7, respectively; both significantly (P < .05) improved to 0.83/79.0/86.8 and 0.89/92.6/85.5, respectively, following the use of e-Stroke predictions as a computer-assisted tool. The interrater agreement (κ) for determination of DWI-FLAIR status was improved from 0.49 to 0.57 following the use of the computer-assisted tool. CONCLUSIONS This automated quantitative approach for DWI-FLAIR mismatch provides results comparable with those of human experts and can improve the diagnostic accuracies of expert neuroradiologists in the determination of DWI-FLAIR status.
Collapse
Affiliation(s)
- E Tavakkol
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - S Kihira
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - M McArthur
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - J Polson
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - H Zhang
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - C W Arnold
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - B Yoo
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - M Linetsky
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - B Salehi
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - L Ledbetter
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - C Kim
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - R Jahan
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - G Duckwiler
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| | - J L Saver
- Department of Neurology (J.L.S., D.S.L.), University of California, Los Angeles, Los Angeles, California
| | - D S Liebeskind
- Department of Neurology (J.L.S., D.S.L.), University of California, Los Angeles, Los Angeles, California
| | - K Nael
- From the Department of Radiological Sciences (E.T., S.K., M.M. J.P., H.Z., C.W.A., B.Y., M.L., B.S., L.L., C.K., R.J., G.D., K.N.), University of California, Los Angeles, Los Angeles, California
| |
Collapse
|
2
|
Mehra R, Mattison LK, Ledbetter L, Ezzeldin H, Diasio RB, Saif MW. Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: Experience of 4 years. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2056 Background: 5-Fluorouracil (5-FU) is an integral part of treatment of GI malignancies. While normal DPD enzyme activity is rate limiting in 5-FU catabolism, its deficiency could increase concentrations of bioavailable 5-FU anabolic products leading to 5-FU related toxicity syndrome. With DPD deficiency, 5-FU is discontinued. Data regarding safety of capecitabine (CAP) in this population is scarce. Methods: Patients were tested for DPD deficiency after excessive toxicities from 5-FU and CAP at UAB between 2001 and 2005. DPD activity was evaluated by PBMC radio assay, genotyping of DPYD gene by DHPLC, or 2-13C uracil breath test (UraBT). Results: Of 23 patients with GI malignancies (small intestine, gastric, pancreatic, HCC, and colorectal) evaluated, 7 (30%) were DPD deficient. Among these 7 patients, DPD activity ranged from 0.064 - 0.18 nmol/min/mg. Age ranged from 51–75 years, M:F ratio = 1.3:1, and ethnicities included Caucasian (71%), African-American (14%) and South-Asian (14%). Four were treated with 5-FU/LV (2 Roswell; 2 Mayo); 2 CAP (1800mg/m2); and 2 high dose bolus 5-FU (1400mg/m2) + PN401 (tri-acetyluridine). Toxicities included mucositis (71%), diarrhea (43%), nausea (29%), memory loss/altered mental status (43%), cytopenias (43%), hypotension (14%), respiratory distress (14%), acute renal failure (14%), and severe skin rashes (43%). Re-challenge with CAP in 1 patient after the Mayo regimen caused grade 3 HFS only on dorsal surfaces of hands. One patient on PN401 had a grade 3 facial rash as the worst toxicity. Genotypic analysis of the DPYD gene in the second on PN401, who had severe leucopenia, demonstrated a heterozygous mutation (IVS14+1 G>A, DPYP*2A). UraBT in 2 patients revealed 1 to be DPD-deficient (DOB50 of 112.8; PDR of 49.4%) and borderline normal values (DOB50 of 130.9; PDR of 52.5%) in a second patient. There were 2 toxicity-related deaths (28%): 1 on CAP and 1 on 5-FU + PN401. Conclusions: DPD deficiency was observed in several ethnicities. Patients with CAP toxicities should also be tested for DPD deficiency. Role of PN401 in rescuing 5-FU toxicity in DPD deficiency is not clear. Screening patients for DPD deficiency prior to administration of 5-FU or CAP, using UraBT, could potentially lower risk of toxicity. Future studies should validate this technique. [Table: see text]
Collapse
Affiliation(s)
- R. Mehra
- Yale University, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL
| | - L. K. Mattison
- Yale University, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL
| | - L. Ledbetter
- Yale University, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL
| | - H. Ezzeldin
- Yale University, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL
| | - R. B. Diasio
- Yale University, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL
| | - M. W. Saif
- Yale University, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|